30 April 2025, Mumbai: Alembic Pharmaceuticals Limited has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug istration (US FDA) for its Oncology Formulation Facility (Injectable and Oral Solid), located at av.
This follows the successful completion of a US FDA inspection conducted at the facility from October 7 to October 8, 2024, as communicated in earlier intimation.
The receipt of the EIR signifies the closure of the inspection process and reinforces Alembic’s commitment to global regulatory compliance and high-quality manufacturing standards.